NAD Looks Promising in EAE Mouse Model of MS

[Guest guest]

I AM NOT A DOCTOR. CONSULT WITH YOUR OWN PHYSICIAN. USE AT YOUR OWN

RISK.

Anyone else check this out? Looks promising . . . this is a product

that contains Nicotinamide adenine dinucleotide (NAD):

http://www.physicianformulas.com/store/Scripts/prodview.asp?

idproduct=32

TAKE AT YOUR OWN RISK. I AM NOT A DOCTOR.

Cheers,

See rationale for taking in newsclip below:

Using a mouse model, researchers at Children's Hospital Boston have

found strong evidence that nicotinamide – a form of vitamin B3 – may

protect against nerve damage in chronic, progressive multiple

sclerosis, which currently has no good treatment. Their findings will

be published Sept. 20 in a cover article in the Journal of

Neuroscience.

Courtesy Shinjiro Kaneko, MD, Neurobiology Program, Children's

Hospital Boston

In mice with MS-like disease, nicotinamide delayed and reduced

neurologic disability as indicated by behavioral scores (1 indicating

mild weakness only in the tail; 4, paralysis involving all four

limbs). Mice receiving placebo (saline) had the most disability,

while mice receiving high-dose nicotinamide had the least. Wlds mice

(which more readily convert nicotinamide to NAD) benefited most from

treatment.

Newswise — Researchers have found a possible way to protect people

with multiple sclerosis (MS) from severe long-term disability:

increase nervous-system levels of a vital compound, called

nicotinamide adenine dinucleotide (NAD), by giving its chemical

precursor – nicotinamide, a form of vitamin B3.

Current therapies for MS mainly address the relapsing-remitting phase

of the disease, but some of these have severe side effects, and most

patients eventually enter a chronic progressive phase for which there

is no good treatment. Using a mouse model of MS, researchers in the

Neurobiology Program at Children's Hospital Boston found strong

evidence that nicotinamide may protect against nerve damage in the

chronic progressive phase, when the most serious disabilities occur.

Their findings appear in a cover article in the September 20 2006

Journal of Neuroscience.